Sam Brusco, Associate Editor06.20.23
BD (Becton, Dickinson and Company) has begun a deal to sell its Surgical Instrumentation platform to STERIS for $540 million.
This divestiture will include BD’s V. Mueller, Snowden-Pencer, and Genesis branded products and three manufacturing facilities located in St. Louis, Cleveland, and Tuttlingen, Germany. About 360 employees supporting the platform will transfer to STERIS as well.
The transaction is expected to close in BD’s fiscal year 2023 (ending Sept. 30). The Surgical Instrumentation platform is part of BD’s Surgery business in its Interventional segment. The Surgical Instrumentation platform has three dedicated manufacturing sites and about 20,000 SKUs in its portfolio, according to BD.
Divesting the platform, according to BD, progresses the “Simplify” pillar of its BD 2025 strategy and is a critical step in simplifying its product portfolio and manufacturing network.
STERIS provides products and services that support infection prevention. The company has $5 billion in global sales with over 17,000 associates. The company serves the healthcare, pharmaceutical, medical device, and dental segments.
BD’s surgical instrumentation platform complements STERIS’ Healthcare segment and will help the company better serve hospital and surgery centers.
"The Surgical Instrumentation platform has a 120-year legacy of providing reliable and trusted high-quality products, and STERIS is well positioned to maximize the value of this extensive portfolio and is fortunate to be adding such a dedicated and talented team to its organization," Rick Byrd, president of the Interventional segment at BD, told the press. "This transaction further advances the BD Interventional segment's focus on high-growth end markets. We look forward to continuing to address unmet needs in health care through a highly differentiated and innovative set of solutions and products."
Last week, BD rolled out the BD FACSDuet premium sample preparation system, an automated instrument that prepares samples for clinical diagnostics using flow cytometry.
This divestiture will include BD’s V. Mueller, Snowden-Pencer, and Genesis branded products and three manufacturing facilities located in St. Louis, Cleveland, and Tuttlingen, Germany. About 360 employees supporting the platform will transfer to STERIS as well.
The transaction is expected to close in BD’s fiscal year 2023 (ending Sept. 30). The Surgical Instrumentation platform is part of BD’s Surgery business in its Interventional segment. The Surgical Instrumentation platform has three dedicated manufacturing sites and about 20,000 SKUs in its portfolio, according to BD.
Divesting the platform, according to BD, progresses the “Simplify” pillar of its BD 2025 strategy and is a critical step in simplifying its product portfolio and manufacturing network.
STERIS provides products and services that support infection prevention. The company has $5 billion in global sales with over 17,000 associates. The company serves the healthcare, pharmaceutical, medical device, and dental segments.
BD’s surgical instrumentation platform complements STERIS’ Healthcare segment and will help the company better serve hospital and surgery centers.
"The Surgical Instrumentation platform has a 120-year legacy of providing reliable and trusted high-quality products, and STERIS is well positioned to maximize the value of this extensive portfolio and is fortunate to be adding such a dedicated and talented team to its organization," Rick Byrd, president of the Interventional segment at BD, told the press. "This transaction further advances the BD Interventional segment's focus on high-growth end markets. We look forward to continuing to address unmet needs in health care through a highly differentiated and innovative set of solutions and products."
Last week, BD rolled out the BD FACSDuet premium sample preparation system, an automated instrument that prepares samples for clinical diagnostics using flow cytometry.